Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.

Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT; ACTG A5001/ALLRT Protocol Team.

Clin Infect Dis. 2011 Apr 1;52(7):929-40. doi: 10.1093/cid/ciq244.


Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sørensen HT.

HIV Med. 2010 Feb;11(2):130-6. doi: 10.1111/j.1468-1293.2009.00751.x. Epub 2009 Aug 13.


Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P.

Clin Infect Dis. 2011 Jul 1;53(1):84-91. doi: 10.1093/cid/cir269.


Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.

Brouwer ES, Napravnik S, Eron JJ Jr, Stalzer B, Floris-Moore M, Simpson RJ Jr, Stürmer T.

Epidemiology. 2014 May;25(3):406-17. doi: 10.1097/EDE.0000000000000041.


Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Arch Intern Med. 2010 Jul 26;170(14):1228-38. doi: 10.1001/archinternmed.2010.197.


Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.

Marcus JL, Neugebauer RS, Leyden WA, Chao CR, Xu L, Quesenberry CP Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):413-9. doi: 10.1097/QAI.0000000000000881.


Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren JD; D:A:D Study Group.

BMC Med. 2016 Mar 31;14:61. doi: 10.1186/s12916-016-0588-4.


No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.

Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):441-7. doi: 10.1097/QAI.0b013e31826f993c.


Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.

Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G.

AIDS. 2011 Oct 23;25(16):1993-2004. doi: 10.1097/QAD.0b013e328349c6ee. Review.


Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):20-8. doi: 10.1097/QAI.0b013e31819ff0e6.


Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

JAMA. 2006 Aug 16;296(7):769-81.


Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Review.


Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team.

JAMA. 2001 Mar 7;285(9):1155-63. Erratum in: JAMA 2001 Jun 13;285(22):2858.


Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.

Palmer M, Chersich M, Moultrie H, Kuhn L, Fairlie L, Meyers T.

AIDS. 2013 Mar 13;27(5):781-5. doi: 10.1097/QAD.0b013e32835c54b8.


Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD.

AIDS. 2003 Sep 26;17(14):2045-52.


Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J.

J Infect Dis. 2010 Feb 1;201(3):318-30. doi: 10.1086/649897.


Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e.


Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.

Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):413-21. doi: 10.1097/QAI.0000000000000662.

Supplemental Content

Support Center